Table 3.

Safety and tolerance within the first 7 days following treatment initiation

Tolerance issues	Total n = 80	Standard of care n = 22	Lopinavir/ritonavir n = 20	Hydroxy-chloroquine n = 38	p value
Neutropenia, n (%)	1 (1)	0 (0)	1 (5)	0 (0)	0.219
Anemia, n (%)	7 (9)	2 (9)	2 (10)	3 (8)	0.962
Thrombocytopenia, n (%)	10 (13)	2 (9)	3 (15)	5 (13)	0.834
Increased aspartate aminotransferase > 5 N, n (%)	20 (25)	6 (27)	7 (35)	7 (18)	0.367
Increased alanine aminotransferase > 5 N, n (%)	14 (18)	3 (14)	3 (15)	8 (21)	0.724
Acute renal failure KDIGO ≥ 2, n (%)	40 (50)	12 (55)	12 (60)	16 (42)	0.381
Prolonged QT interval*, n (%)	1 (1)	0 (0)	0 (0)	1 (3)	0.571

Categorical variables are expressed as absolute value (%). p values are given for the comparison between groups of treatment

KDIGO Kidney disease improving global outcome

*QT interval is prolonged when > 450 ms in men and > 470 ms in women